Suppr超能文献

终末期肾病患者持续非卧床腹膜透析时糖尿病患者的血糖高估情况。

Blood glucose overestimation in diabetic patients on continuous ambulatory peritoneal dialysis for end-stage renal disease.

作者信息

Oyibo Samson O, Pritchard G M, McLay L, James E, Laing I, Gokal R, Boulton A J M

机构信息

Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK.

出版信息

Diabet Med. 2002 Aug;19(8):693-6. doi: 10.1046/j.1464-5491.2002.00753.x.

Abstract

AIMS

Diabetic patients on continuous ambulatory peritoneal dialysis (CAPD) for renal failure depend on glucose analysers for regular monitoring of glycaemic control. We aim to inform health professionals of the potentially dangerous overestimation of blood glucose values by some analysers in patients using Icodextrin for dialysis.

METHODS

Twenty-five patients on continuous ambulatory peritoneal dialysis (10 patients on an 8-12-h nocturnal exchange of Icodextrin) had random glucose analysis performed on venous blood using standardized reference laboratory (lab) technique (glucose oxidase GOD-PAP), and simultaneously on capillary blood using the Precision Q.I.D System (glucose oxidase method) and the Advantage meter (glucose dehydrogenase method).

RESULTS

The Precision Q.I.D System agreed with the lab results in both the Icodextrin group and the non-Icodextrin group (80-90% of values fell within 20% of the corresponding lab result). In contrast, the Advantage meter agreed with the lab results only in the non-Icodextrin group (95% of values within 20% of the corresponding lab value), and not in the Icodextrin group, where only 5% of the analyser values fell within 20% of the corresponding lab value.

CONCLUSIONS

The Precision Q.I.D System, which utilizes glucose oxidase reaction, is safe for use in diabetic patients treated with Icodextrin. All analysers must be cross-checked with the laboratory reference method before use in these patients.

摘要

目的

因肾衰竭接受持续性非卧床腹膜透析(CAPD)的糖尿病患者依赖血糖仪定期监测血糖控制情况。我们旨在告知医疗专业人员,对于使用艾考糊精进行透析的患者,某些血糖仪可能会危险地高估血糖值。

方法

25名接受持续性非卧床腹膜透析的患者(10名患者进行8 - 12小时夜间艾考糊精交换),使用标准化参考实验室技术(葡萄糖氧化酶GOD - PAP法)对静脉血进行随机血糖分析,同时使用Precision Q.I.D系统(葡萄糖氧化酶法)和Advantage血糖仪(葡萄糖脱氢酶法)对毛细血管血进行血糖分析。

结果

Precision Q.I.D系统在艾考糊精组和非艾考糊精组中均与实验室结果相符(80 - 90%的值落在相应实验室结果的20%范围内)。相比之下,Advantage血糖仪仅在非艾考糊精组与实验室结果相符(95%的值在相应实验室值的20%范围内),而在艾考糊精组中不相符,该组中只有5%的血糖仪值落在相应实验室值的20%范围内。

结论

采用葡萄糖氧化酶反应的Precision Q.I.D系统对于接受艾考糊精治疗的糖尿病患者使用是安全的。在这些患者中使用所有血糖仪之前,都必须与实验室参考方法进行交叉核对。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验